Key result
US and European guidelines show strong alignment on CV risk reduction strategies in T2D.
Answers are grounded in this paper and cite their sources.
Professional society guidelines from the US and Europe show considerable alignment on cardiovascular risk reduction strategies for patients with type 2 diabetes.
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.
No takes yet. Share an insight, caveat, or question.
Kelsey et al. (2022) conducted a review in Type 2 diabetes mellitus. Cardiovascular risk reduction guidelines was evaluated. Guidelines from various professional societies in the United States and Europe show considerable alignment regarding cardiovascular risk reduction in patients with type 2 diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: